Individual Abstract within a Delegate Designed Symposium Clinical Oncology Society of Australia Annual Scientific Meeting 2019

Evolving molecular imaging and radionuclide therapies in prostate cancer (#48)

Nat Lenzo 1 2
  1. Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia
  2. GenesisCare, Alexandria, NSW, Australia

The last decade has seen the development and implementation of molecular imaging techniques that are changing the management paradigms of prostate cancer.  Despite widespread clinical acceptance in countries such as Australia and Germany these imaging agents have yet to obtain formal regulatory approval in most countries and also their role in various clinical scenarios have yet to be fully determined. These new targeted imaging agents have also directly lead to the development of targeted therapeutic agents using beta emitters such as Lutetium-177 and now alpha emitters such as Actinium-225. This dual imaging-therapy paradigm is known colloquially as Theranostics though the principles of this branch of medicine date back to Iodine-131 therapy used for imaging and treating thyroid cancer since 1943. In this symposium we will explore the development and emerging role of molecular imaging in the management of prostate cancer and also the growing body of data on the use and potential role of targeted radionuclide therapies, such as Lu-177 PSMA and Ac-225 PSMA, in the management of advanced (and not so advanced) prostate cancer.

 

LEARNING OBJECTIVES:

To better understand the role of the new molecular imaging agents (Ga-PSMA, F-PSMA and similar analogues) in the management of prostate cancer patients.

To consider the role of targeted radionuclide imaging and therapy in current and future management of prostate cancer.. 

To update on the new advances in this area (e.g. Ac-225 PSMA, combination therapy) and ongoing clinical trials in this space.

  1. Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer Nat P. Lenzo, Danielle Meyrick, J. Harvey Turner Diagnostics (Basel) 2018 Mar; 8(1): 16.
  2. Wester HJ, Schottelius M. PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy. Semin Nucl Med. 2019 Jul;49(4):302-312.
  3. Farolfi A, Fendler W, Iravani A, Haberkorn U, Hicks R, Herrmann K, Walz J, Fanti S. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. Eur Urol Oncol. 2019 Mar;2(2):152-162.